Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: A systematic review of observational and intervention studies

Blood Coagulation and Fibrinolysis

Volumn 22, Issue 2, 2011, Pages 86-91

  Louzada, Martha L ^a   Majeed, Habeeb ^b   Dao, Vi ^c   Wells, Philip S ^b,d  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Cancer; malignancy; primary tumour site; recurrence; tumour histology; venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; LOW MOLECULAR WEIGHT HEPARIN;

ADENOCARCINOMA; ANTICOAGULATION; ARTICLE; BREAST CANCER; CANCER LOCALIZATION; CANCER STAGING; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; LUNG EMBOLISM; META ANALYSIS (TOPIC); METASTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BREAST NEOPLASMS; FEMALE; GASTROINTESTINAL NEOPLASMS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; RECURRENCE; RISK; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 79951674716     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328341f030     Document Type: Article

References (29)

1. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ III. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000; 160:761-768. (Pubitemid 30165236)
2. Boccaccio C, Comoglio PM. A functional role for hemostasis in early cancerdevelopment. CancerRes 2005; 65:8579-8582. (Pubitemid 41377338)
3. Pinedo HM, Verheul HM, D'Amato RJ, Folkman J. Involvement of platelets in tumour angiogenesis? Lancet 1998; 352:1775-1777. (Pubitemid 28534972)
4. Mechtcheriakova D, Wlachos A, Holzmuller H, Binder BR, Hofer E. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood 1999; 93:3811-3823. (Pubitemid 29249828)
5. Louzada ML, Majeed H, Wells PS. Efficacyoflowmolecularweight heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb Res 2008; 123:837-844.
6. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, et al. American Society of Clinical Oncology guideline: recommendations forvenous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25:5490-5505. (Pubitemid 350232226)
7. Mandala M, Falanga A, Roila F. Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol2008; 19 (Suppl 2):ii126-ii127.
8. Prandoni P, LensingAW, Piccioli A, Bernardi E, Simioni P, Girolami B, etal. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood2002; 100:3484-3488.
9. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293:715-722. (Pubitemid 40216041)
10. Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66 329 cancerpatients: resultsofarecord linkagestudy.J Thromb Haemost 2006; 4:529-535.
11. Monreal M, Zacharski L, Jimenez JA, Roncales J, Vilaseca B. Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. J Thromb Haemost 2004; 2:1311-1315. (Pubitemid 40186126)
12. Wells G, Shea B, O'Connell, Peterson J, Welch V, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2008. www.ohri.ca/programs/clinical-epidemiology/oxford.htm.
13. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM Statement. Onkologie 2000; 23:597-602. (Pubitemid 32046061)
14. Greene FL, Page D, Morrow M, Balch C, Haller D, Fritz A, Fleming I. AJCC (American Joint Committee on Cancer) cancer staging manual, 6th ed. New York: Springer; 2002.
15. Constantini S, Kornowski R, Pomeranz S, Rappaport ZH. Thromboembolic phenomena in neurosurgical patients operated upon for primary and metastatic brain tumors. Acta Neurochir (Wien) 1991; 109:93-97.
16. Debourdeau P, Meyer G, Sayeg H, Marjanovic Z, Bastit L, Cabane J, et al. Classical anticoagulant treatment of venous thromboembolic disease in cancerpatients. Aproposof aretrospectivestudyof 71 patients [in French]. Revue de Medecine Interne 1996; 17:207-212. (Pubitemid 26133009)
17. Schiff D, DeAngelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer 1994; 73:493-498. (Pubitemid 24030634)
18. Clarke-Pearson DL, Synan IS, Creasman WT. Anticoagulation therapy for venous thromboembolism in patients with gynecologic malignancy. Am J Obstet Gynecol1983; 147:369-375. (Pubitemid 13012309)
19. Descourt R, Le Gal G, Couturaud F, Mottier D, Bressollette L, Robinet G, et al. Recurrent venous thromboembolism under anticoagulant therapy: a high risk in adenocarcinoma? Thromb Haemost 2006; 95:912-913.
20. Sallah S, Husain A, Sigounas V, Wan J, Turturro F, Sigounas G, Nguyen NP. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. Clin Cancer Res 2004; 10:7238-7243. (Pubitemid 39487710)
21. Trujillo-Santos J, Nieto JA, Tiberio G, Piccioli A, Di Micco P, Prandoni P, Monreal M. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE registry. Thromb Haemost2008; 100:435-439.
22. De Stefano V, Sora F, Rossi E, Chiusolo P, Laurenti L, Fianchi L, et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 2005; 3:1985-1992. (Pubitemid 43086055)
23. Tagalakis V, Levi D, AgulnikJS, Cohen V, Kasymjanova G, Small D. High riskof deep vein thrombosis in patients with non-small cell lung cancer: a cohort study of 493 patients. J Thorac Oncol 2007; 2:729-734. (Pubitemid 47357525)
24. Elting LS, Escalante CP, Cooksley C, Avritscher EB, Kurtin D, Hamblin L, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2009; 164:1653-1661. (Pubitemid 39037944)
25. Lee AY, Parpia S, Julian J, Rickles F, Prins M, Levine M. Risk factors for recurrentthrombosisand anticoagulant-related bleeding in cancerpatients [abstract]. In: Program and Abstracts of the 22nd ISTH Congress; 11-16 July 2009; Boston, MA. J Thromb Haemost 2009; 5 (Suppl 2):OC-MO-016.
26. Levitan N, Dowlati A, RemickSC,Tahsildar HI, Sivinski LD, Beyth RJ, Rimm AA. Rates of initial and recurrentthromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine 1999; 78:285-291. (Pubitemid 29439263)
27. BlomJW,OsantoS, Rosendaal FR.Theriskof avenousthromboticevent in lung cancer patients: higher riskfor adenocarcinoma than squamous cell carcinoma. J Thromb Haemost 2004; 2:1760-1765. (Pubitemid 40192717)
28. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus acoumarinforthe prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349:146-153. (Pubitemid 36818784)
29. Noble SI, Shelley MD, Coles B, Williams SM, Wilcock A, Johnson MJ, Association for Palliative Medicine for Great Britain and Ireland. Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis [review]]. Lancet Oncol 2008; 9:577-584. (Pubitemid 351735054)